$SGMO
Sangamo Therapeutics Inc

2014 Q4 Form 10-Q Financial Statement

#000156459014004591 Filed on October 28, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $14.95M $12.42M $5.707M
YoY Change 117.67% 117.57% 16.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.330M $3.730M $3.160M
YoY Change 5.35% 18.04% 0.64%
% of Gross Profit
Research & Development $14.99M $16.29M $8.703M
YoY Change 39.05% 87.18% 14.97%
% of Gross Profit
Depreciation & Amortization $100.0K $100.0K $100.0K
YoY Change -50.0% 0.0% -50.0%
% of Gross Profit
Operating Expenses $19.42M $20.07M $11.87M
YoY Change 29.1% 69.15% 10.8%
Operating Profit -$6.159M
YoY Change 6.15%
Interest Expense $150.0K $110.0K $10.00K
YoY Change 400.0% 1000.0% 0.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.320M -$7.545M -$6.150M
YoY Change -46.93% 22.68% 6.22%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.319M -$7.545M -$6.145M
YoY Change -46.97% 22.78% 6.13%
Net Earnings / Revenue -28.89% -60.76% -107.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$62.96K -$110.7K -$112.2K
COMMON SHARES
Basic Shares Outstanding 68.40M 68.16M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $226.2M $162.4M $120.2M
YoY Change 63.44% 35.11% 107.6%
Cash & Equivalents $6.030M $11.21M $80.31M
Short-Term Investments $220.2M $151.2M $39.90M
Other Short-Term Assets $183.0K $887.0K $149.0K
YoY Change -4.19% 495.3% -78.71%
Inventory
Prepaid Expenses $623.0K $751.0K $684.0K
Receivables $10.37M $8.474M $4.880M
Other Receivables $400.0K $300.0K $200.0K
Total Short-Term Assets $190.9M $173.2M $126.1M
YoY Change 96.23% 37.28% 102.15%
LONG-TERM ASSETS
Property, Plant & Equipment $1.479M $1.566M $1.494M
YoY Change 5.19% 4.82% -0.4%
Goodwill $1.585M $1.585M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $47.30M $69.00M $12.70M
YoY Change 22.22% 443.31% -29.05%
Other Assets $139.0K $108.0K $0.00
YoY Change 247.5%
Total Long-Term Assets $52.33M $74.18M $14.22M
YoY Change 20.13% 421.54% -26.69%
TOTAL ASSETS
Total Short-Term Assets $190.9M $173.2M $126.1M
Total Long-Term Assets $52.33M $74.18M $14.22M
Total Assets $243.2M $247.3M $140.4M
YoY Change 72.69% 76.22% 71.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.525M $8.000M $2.700M
YoY Change 82.83% 196.3% 58.82%
Accrued Expenses $3.400M $2.700M $2.000M
YoY Change -8.11% 35.0% 11.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.88M $19.49M $7.004M
YoY Change 106.12% 178.33% 16.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $14.90M $17.00M $7.200M
YoY Change 81.71% 136.11% -23.4%
Total Long-Term Liabilities $14.90M $17.00M $7.200M
YoY Change 81.71% 136.11% -23.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.88M $19.49M $7.004M
Total Long-Term Liabilities $14.90M $17.00M $7.200M
Total Liabilities $36.58M $37.21M $14.23M
YoY Change 91.23% 161.57% -7.63%
SHAREHOLDERS EQUITY
Retained Earnings -$328.6M -$324.2M -$294.0M
YoY Change 8.74% 10.29%
Common Stock $535.2M $534.3M $614.0K
YoY Change 26.28% 86922.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $206.6M $210.1M $126.1M
YoY Change
Total Liabilities & Shareholders Equity $243.2M $247.3M $140.4M
YoY Change 72.69% 76.22% 71.6%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$4.319M -$7.545M -$6.145M
YoY Change -46.97% 22.78% 6.13%
Depreciation, Depletion And Amortization $100.0K $100.0K $100.0K
YoY Change -50.0% 0.0% -50.0%
Cash From Operating Activities -$2.700M -$5.800M -$4.500M
YoY Change 58.82% 28.89% -13.46%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$100.0K -$100.0K
YoY Change 0.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities -$200.0K -$83.40M $1.300M
YoY Change -99.71% -6515.38%
Cash From Investing Activities -$400.0K -$83.40M $1.300M
YoY Change -99.42% -6515.38% -750.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.100M 1.200M 71.50M
YoY Change -520.0% -98.32% 14200.0%
NET CHANGE
Cash From Operating Activities -2.700M -5.800M -4.500M
Cash From Investing Activities -400.0K -83.40M 1.300M
Cash From Financing Activities -2.100M 1.200M 71.50M
Net Change In Cash -5.200M -88.00M 68.30M
YoY Change -92.58% -228.84% -1493.88%
FREE CASH FLOW
Cash From Operating Activities -$2.700M -$5.800M -$4.500M
Capital Expenditures $0.00 -$100.0K -$100.0K
Free Cash Flow -$2.700M -$5.700M -$4.400M
YoY Change 58.82% 29.55% -13.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
457000
CY2013Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
38663000
CY2013Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1870000
CY2013Q4 sgmo Escrow Liability
EscrowLiability
275000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2282000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10131000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
320000
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
191000
CY2014Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1870000
CY2014Q3 us-gaap Goodwill
Goodwill
1585000
CY2014Q3 sgmo Escrow Liability
EscrowLiability
275000
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8556000
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
19494000
CY2014Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
15266000
CY2014Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
751000
CY2013Q4 us-gaap Goodwill
Goodwill
1585000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
40000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10186000
CY2014Q3 us-gaap Other Assets Current
OtherAssetsCurrent
887000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1566000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
173169000
CY2014Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
320000
CY2014Q3 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
69049000
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
68403973
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11205000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
97274000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1406000
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
108000
CY2014Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
151219000
CY2013Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
338000
CY2013Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
82627000
CY2014Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
313000
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8474000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3155000
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4380000
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Assets
Assets
140838000
CY2013Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3194000
CY2014Q3 us-gaap Assets
Assets
247347000
CY2014Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7999000
CY2014Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2664000
CY2014Q3 us-gaap Liabilities
Liabilities
37208000
CY2013Q4 us-gaap Liabilities
Liabilities
19128000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6135000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
75627000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-25000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
18000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5319000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
696000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1059000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
387000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3619000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1348000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-530000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-434000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
14861000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1630000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2963000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17825000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
176385000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
37161000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
76605000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
38384000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
559000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
395000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-100339000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
828000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10525000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
58630000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-6145000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-7545000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7525000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6118000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
12000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
121710000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
423209000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-302133000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
41000
us-gaap Net Income Loss
NetIncomeLoss
-22098000
us-gaap Net Income Loss
NetIncomeLoss
-18480000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66488000
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54786000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22057000
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
27000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68230000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-843000
us-gaap Share Based Compensation
ShareBasedCompensation
6165000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value measurements, business combinations including the fair value of the contingent consideration liability for payments to former Ceregene, Inc. (&#8220;Ceregene&#8221;) stockholders and intangible assets related to the acquisition of Ceregene, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </p></div>
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6679000
CY2014Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1700000
CY2013Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1570000
CY2014Q3 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
748000
CY2013Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
748000
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
683000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
622000
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
533634000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-324231000
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
53000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
210139000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
247347000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
140838000
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68333273
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62243892
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68333273
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62243892
CY2014Q3 sgmo Collaboration Agreements
CollaborationAgreements
12045000
CY2013Q3 sgmo Collaboration Agreements
CollaborationAgreements
4825000
sgmo Collaboration Agreements
CollaborationAgreements
29334000
sgmo Collaboration Agreements
CollaborationAgreements
15065000
CY2014Q3 us-gaap Revenue From Grants
RevenueFromGrants
372000
CY2013Q3 us-gaap Revenue From Grants
RevenueFromGrants
882000
us-gaap Revenue From Grants
RevenueFromGrants
1584000
CY2014Q3 us-gaap Revenues
Revenues
12417000
CY2013Q3 us-gaap Revenues
Revenues
5707000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16290000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9595000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
130000
us-gaap Operating Expenses
OperatingExpenses
53230000
us-gaap Operating Expenses
OperatingExpenses
35796000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6159000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22312000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18532000
CY2014Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
109000
CY2013Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
14000
us-gaap Interest And Other Income
InterestAndOtherIncome
214000
us-gaap Interest And Other Income
InterestAndOtherIncome
52000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54013000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18480000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
445000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-625000
us-gaap Share Based Compensation
ShareBasedCompensation
4098000
sgmo Net Proceeds From Issuance Public Offering
NetProceedsFromIssuancePublicOffering
93796000
sgmo Net Proceeds From Issuance Public Offering
NetProceedsFromIssuancePublicOffering
69492000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
104321000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1019000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21679000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80309000
CY2014Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
227461000
CY2014Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1700000
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2014Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
CY2014Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
227461000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
128224000
CY2014Q3 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2013Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
128224000
CY2013Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1570000
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1570000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
130000
CY2014Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1700000
CY2014Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
227408000
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
128212000
CY2014Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
64000
CY2013 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2014Q1 sgmo Number Of Research Program
NumberOfResearchProgram
2
CY2014Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
20000000
us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2129000
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1391000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6165000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4098000
CY2014Q1 sgmo Net Proceeds From Issuance Public Offering
NetProceedsFromIssuancePublicOffering
93796000

Files In Submission

Name View Source Status
0001564590-14-004591-index-headers.html Edgar Link pending
0001564590-14-004591-index.html Edgar Link pending
0001564590-14-004591.txt Edgar Link pending
0001564590-14-004591-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgmo-10q_20140930.htm Edgar Link pending
sgmo-20140930.xml Edgar Link completed
sgmo-20140930.xsd Edgar Link pending
sgmo-20140930_cal.xml Edgar Link unprocessable
sgmo-20140930_def.xml Edgar Link unprocessable
sgmo-20140930_lab.xml Edgar Link unprocessable
sgmo-20140930_pre.xml Edgar Link unprocessable
sgmo-ex101_20140930757.htm Edgar Link pending
sgmo-ex102_20140930559.htm Edgar Link pending
sgmo-ex311_201409306.htm Edgar Link pending
sgmo-ex312_201409307.htm Edgar Link pending
sgmo-ex321_201409308.htm Edgar Link pending
Show.js Edgar Link pending